DUBLIN–(BUSINESS WIRE)–The “Research Report on China’s Anastrozole Market, 2021-2025” report has been added to ResearchAndMarkets.com’s offering.
Anastrozole was developed by AstraZeneca with Arimidex as its trade name. And it was first marketed in the United States in 1995, approved by the FDA of U.S. for the treatment of advanced breast cancer in postmenopausal women.
1999 saw the introduction of AstraZeneca’s anastrozole into China, where it was approved for use in the adjuvant treatment of estrogen receptor-positive early-stage breast cancer in postmenopausal women. In the following years, generic versions of anastrozole were launched by local Chinese companies. According to the publisher’s market research, AstraZeneca still occupied more than 80% of China’s anastrozole market share in 2020 in terms of market value, thus having a huge competitive advantage.
According to the publisher’s survey data, the sales value of anastrozole in China kept increasing year by year from 2016 to 2020, not much impacted by COVID-19. In 2020, the sales value of anastrozole in China was about CNY452 million, with a CAGR of 12.1% from 2016 to 2020.
The publisher expects that with the rising incidence of breast cancer in China, anastrozole still has significant room for growth in the Chinese market. In addition, compared with other drugs of the same category, anastrozole has been clinically used earlier and is reimbursable under the medical insurance with little cost, and it has relatively fewer side effects as well.
Some studies suggest that anastrozole may reduce the risk of invasive estrogen receptor-positive breast cancer and ductal carcinoma in situ in a high-risk postmenopausal breast population.
New indications for anastrozole are also expected to be approved in China soon. According to the publisher’s estimation, from 2021 to 2025, the sales volume and value of anastrozole in China will continue to grow.
Topics Covered:
Key Topics Covered:
1 Relevant Concept of Anastrozole
1.1 Indications of Anastrozole
1.2 Development of China’s Anastrozole Market
1.3 Governmental Approval of Anastrozole in China
1.4 The Impact of COVID-19 on China’s Anastrozole Market
2 Sales of Anastrozole in China, 2016-2020
2.1 Sales Value
2.1.1 Sales Value in China
2.1.2 Sales Value in China by Region
2.2 Sales Volume
2.2.1 Sales Volume in China
2.2.2 Sales Volume in China by Region
2.3 Sales of Anastrozole in China by Dosage Form, 2016-2020
2.3.1 Tablets
2.3.2 Other Dosage Forms
3 Analysis of Major Anastrozole Manufacturers in China, 2020
3.1 Analysis of Market Share
3.1.1 Market Share of Manufacturers by Sales Value
3.1.2 Market Share of Manufacturers by Sales Volume
3.2 AstraZeneca UK Ltd
3.2.1 Company Profile
3.2.2 Sales of Anastrozole in China
3.3 Jiangsu Haian Pharmaceutical Co., Ltd.
3.3.1 Company Profile
3.3.2 Sales of Anastrozole in China
3.4 Chongqing Huapont Pharmaceutical Co., Ltd.
3.4.1 Company Profile
3.4.2 Sales of Anastrozole in China
3.5 Zhejiang Hisun Pharmaceutical Co., Ltd.
3.5.1 Company Profile
3.5.2 Sales of Anastrozole in China
3.6 Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
3.6.1 Company Profile
3.6.2 Sales of Anastrozole in China
4 Sales Price of Anastrozole of Different Companies in China, 2020-2021
4.1 AstraZeneca UK Ltd (Arimidex)
4.2 Jiangsu Haian Pharmaceutical Co., Ltd. (AiDa)
4.3 Chongqing Huapont Pharmaceutical Co., Ltd. (RuiTing)
4.4 Zhejiang Hisun Pharmaceutical Co., Ltd. (YiShuZhi)
4.5 Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. (XiangNa)
5 Prospects of China’s Anastrozole Market, 2021-2025
5.1 Influencing Factors for the Market Development
5.1.1 The Impact of COVID-19 on the Market
5.1.2 Market Drivers and Opportunities
5.1.3 Market Threats and Challenges
5.2 Forecast on Market Size
5.3 Forecast on Market Trend
For more information about this report visit https://www.researchandmarkets.com/r/z3i3ok.
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
“Engineered for Sustainability: Hong Kong’s Contribution to United Nations Sustainable Development Goals” Showcasing over 40…
Delta Dunia Group, via its indirect subsidiary BUMA International [1], will expand its presence in…
SINGAPORE - Media OutReach Newswire - 25 November 2024 - FBS, a leading global broker,…
Exploring the Unique Characteristics of Tsuen Wan and Sha Tau Kok and Presenting Hong Kong’s…
A Collaborative Platform Showcasing Scalable and Affordable Solutions for Climate Action, With a Focus on…
Reducing waste by collaborating with the World Green Organisation and a local farm to upcycle…
